The active digitalization of the healthcare system has given impetus to the emergence of a new type of enterprise—high-tech medical organizations (HMO). Their main distinguishing feature is the use of innovative high-tech medical equipment. However, the high cost of this equipment has become a factor slowing down the development of such organizations. This paper considers the life-cycle contract (LCC) as a special form of interaction between stakeholders and investments throughout the life cycles of equipment. Moreover, to provide technological support, continuous acquisition and life-cycle support (CALS) technologies, which are based on the same principles of working with the life cycle as LCC, are proposed. This question turned out to be a significant research gap, which was not sufficiently reflected in the available world studies. Thus, the aim of the current study is to describe the features of the use of LCC for HMO using CALS technologies and the impact of the life cycle of high-tech medical equipment on LCC, as well as to present the innovative component of the proposed model. Based on the analysis of the literature and the best world practices, the authors propose a visualization of the interaction of all stakeholders within the LCC for HMO. Such a decision is extremely relevant for developing organizations, public authorities and investors around the world.

The COVID-19 pandemic has severely tested humanity, revealing the need to develop and improve the medical, economic, managerial, and IT components of vaccine management systems. The vaccine lifecycle includes vaccine research and development, production, distribution, and vaccination of the population. To manage this cycle effectively the proper organizational and IT support model of the interaction of vaccine lifecycle management stakeholders is needed—which are an innovation ecosystem and an appropriate virtual platform. A literature review has revealed the lack of methodological basis for the vaccine innovation ecosystem and virtual platform. This article is devoted to the development of a complex approach for the development of an innovation ecosystem based on vaccine lifecycle management and a virtual platform which provides the data exchange environment and IT support for the ecosystem stakeholders. The methodological foundation of the solution, developed in the article, is an enterprise architecture approach, CALS technologies, supply chain management and an open innovation philosophy. The results, presented in the article, are supposed to be a reference set of models for the creation of a vaccine innovation ecosystem, both during pandemics and periods of stable viral load.

No abstract